MX2020003339A - Arn guía de cpf1 modificado. - Google Patents
Arn guía de cpf1 modificado.Info
- Publication number
- MX2020003339A MX2020003339A MX2020003339A MX2020003339A MX2020003339A MX 2020003339 A MX2020003339 A MX 2020003339A MX 2020003339 A MX2020003339 A MX 2020003339A MX 2020003339 A MX2020003339 A MX 2020003339A MX 2020003339 A MX2020003339 A MX 2020003339A
- Authority
- MX
- Mexico
- Prior art keywords
- nucleic acid
- guide rna
- provides
- cpf1 guide
- modified cpf1
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3519—Fusion with another nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
La invención proporciona un ácido nucleico que comprende un ARNcr de Cpf1, una secuencia de procesamiento 5' del ARNcr de Cpf1, y una secuencia de extensión 5' de la secuencia de procesamiento. La invención también proporciona una composición que comprende el ácido nucleico, un portador y opcionalmente Cpf1. Adicionalmente, la invención proporciona un método para modificar genéticamente una célula diana eucariota, que comprende poner en contacto la célula diana eucariota con el ácido nucleico o la composición para modificar genéticamente un ácido nucleico diana en la célula.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762567123P | 2017-10-02 | 2017-10-02 | |
US201862617138P | 2018-01-12 | 2018-01-12 | |
US201862697327P | 2018-07-12 | 2018-07-12 | |
PCT/US2018/054027 WO2019070762A1 (en) | 2017-10-02 | 2018-10-02 | RNA GUIDE CPF1 MODIFIED |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020003339A true MX2020003339A (es) | 2020-11-06 |
Family
ID=64184173
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020003339A MX2020003339A (es) | 2017-10-02 | 2018-10-02 | Arn guía de cpf1 modificado. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20200299689A1 (es) |
EP (1) | EP3692154A1 (es) |
JP (1) | JP2020537540A (es) |
KR (1) | KR20200106485A (es) |
CN (1) | CN111770994A (es) |
AU (1) | AU2018345683A1 (es) |
BR (1) | BR112020006601A2 (es) |
CA (1) | CA3077189A1 (es) |
IL (1) | IL273595A (es) |
MX (1) | MX2020003339A (es) |
SG (1) | SG11202003083PA (es) |
WO (1) | WO2019070762A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018170184A1 (en) | 2017-03-14 | 2018-09-20 | Editas Medicine, Inc. | Systems and methods for the treatment of hemoglobinopathies |
EP3622070A2 (en) | 2017-05-10 | 2020-03-18 | Editas Medicine, Inc. | Crispr/rna-guided nuclease systems and methods |
EP3652312A1 (en) | 2017-07-14 | 2020-05-20 | Editas Medicine, Inc. | Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites |
US11268092B2 (en) | 2018-01-12 | 2022-03-08 | GenEdit, Inc. | Structure-engineered guide RNA |
GB201905651D0 (en) * | 2019-04-24 | 2019-06-05 | Lightbio Ltd | Nucleic acid constructs and methods for their manufacture |
CN113234701B (zh) * | 2020-10-20 | 2022-08-16 | 珠海舒桐医疗科技有限公司 | 一种Cpf1蛋白及基因编辑系统 |
EP4256040A1 (en) * | 2020-12-07 | 2023-10-11 | Inscripta, Inc. | Grna stabilization in nucleic acid-guided nickase editing |
WO2023201270A2 (en) * | 2022-04-13 | 2023-10-19 | Caribou Biosciences, Inc. | Therapeutic applications of crispr type v systems |
WO2024006672A2 (en) * | 2022-06-27 | 2024-01-04 | University Of Massachusetts | Modified guide rnas for crispr genome editing |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4863457A (en) | 1986-11-24 | 1989-09-05 | Lee David A | Drug delivery device |
US5378475A (en) | 1991-02-21 | 1995-01-03 | University Of Kentucky Research Foundation | Sustained release drug delivery devices |
US5443505A (en) | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
CN106244591A (zh) * | 2016-08-23 | 2016-12-21 | 苏州吉玛基因股份有限公司 | 修饰crRNA在CRISPR/Cpf1基因编辑系统中的应用 |
-
2018
- 2018-10-02 BR BR112020006601-0A patent/BR112020006601A2/pt unknown
- 2018-10-02 JP JP2020539688A patent/JP2020537540A/ja active Pending
- 2018-10-02 AU AU2018345683A patent/AU2018345683A1/en active Pending
- 2018-10-02 WO PCT/US2018/054027 patent/WO2019070762A1/en unknown
- 2018-10-02 MX MX2020003339A patent/MX2020003339A/es unknown
- 2018-10-02 SG SG11202003083PA patent/SG11202003083PA/en unknown
- 2018-10-02 CA CA3077189A patent/CA3077189A1/en active Pending
- 2018-10-02 CN CN201880077637.7A patent/CN111770994A/zh active Pending
- 2018-10-02 KR KR1020207012638A patent/KR20200106485A/ko not_active Application Discontinuation
- 2018-10-02 EP EP18799900.8A patent/EP3692154A1/en active Pending
- 2018-10-02 US US16/753,293 patent/US20200299689A1/en active Pending
-
2020
- 2020-03-25 IL IL273595A patent/IL273595A/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20200106485A (ko) | 2020-09-14 |
SG11202003083PA (en) | 2020-05-28 |
IL273595A (en) | 2020-05-31 |
US20200299689A1 (en) | 2020-09-24 |
WO2019070762A1 (en) | 2019-04-11 |
CA3077189A1 (en) | 2019-04-11 |
BR112020006601A2 (pt) | 2020-12-08 |
JP2020537540A (ja) | 2020-12-24 |
CN111770994A (zh) | 2020-10-13 |
EP3692154A1 (en) | 2020-08-12 |
AU2018345683A1 (en) | 2020-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020003339A (es) | Arn guía de cpf1 modificado. | |
MX2020004578A (es) | Composiciones de casz y metodos de uso. | |
NZ738689A (en) | Engineered crispr-cas9 compositions and methods of use | |
WO2018148647A3 (en) | Genome editing reagents and their use | |
MX2019003674A (es) | Enzimas modificadoras de ácido nucleico guiadas por arn y métodos de uso de estas. | |
EP4361261A3 (en) | Novel cas13b orthologues crispr enzymes and systems | |
PH12021550805A1 (en) | Methods and Compositions for Editing RNAs | |
WO2017216771A3 (en) | Crispr-cas system, materials and methods | |
MX2019011040A (es) | Composiciones y metodos para potenciar la expresion genica. | |
GB2569734A (en) | RNA-guided nucleic acid modifying enzymes and methods of use thereof | |
WO2018191715A3 (en) | Polypeptides with type v crispr activity and uses thereof | |
MX2020011939A (es) | Nuevas enzimas y sistemas crispr. | |
SG10201805815YA (en) | Rna-guided gene drives | |
MX2020006072A (es) | Métodos y composiciones relacionados con cpf1 para la edición genica. | |
MX2022001018A (es) | Electrodos metalicos de bajo costo. | |
MX2021012645A (es) | Metodos y composiciones para editar acidos ribonucleicos (arn). | |
EP3699280A3 (en) | Novel cas9 systems and methods of use | |
BR112018076190A2 (pt) | ortólogos e sistemas crispr tipo vi | |
WO2018015936A3 (en) | Methods and compositions for modifying genomic dna | |
MX2022007575A (es) | Anticuerpos anti cumulo de diferenciacion 73 (cd73) y usos de estos. | |
BR112019023377A2 (pt) | Criação de um gene resistente a herbicida e uso do mesmo | |
EP3845640A3 (en) | Modified tranposases for improved insertion sequence bias and increased dna input tolerence | |
BR112016014022A2 (pt) | anticorpos anti-cd3, ácido nucleico isolado, vetor, célula hospedeira, método de produção do anticorpo anti-cd3, imunoconjugado, composição, uso do anticorpo anti-cd3, métodos de tratamento, métodos de intensificação da função imune e kit | |
WO2018094356A3 (en) | Compositions and methods for target nucleic acid modification | |
WO2018170614A8 (zh) | 基因组大片段直接克隆和dna多分子组装新技术 |